These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33390132)

  • 21. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.
    Kao YR; Chen J; Narayanagari SR; Todorova TI; Aivalioti MM; Ferreira M; Ramos PM; Pallaud C; Mantzaris I; Shastri A; Bussel JB; Verma A; Steidl U; Will B
    Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy.
    Zuo S; Sun L; Wang Y; Chen B; Wang J; Ge X; Lu Y; Yang N; Shen P
    Cell Death Dis; 2021 Feb; 12(2):208. PubMed ID: 33627636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
    Imbach P; Crowther M
    N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
    [No Abstract]   [Full Text] [Related]  

  • 25. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
    Neunert CE
    Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist.
    Abe M; Suzuki K; Sakata C; Sugasawa K; Hirayama F; Koga Y; Kawasaki T; Naganuma S; Itoh H
    Eur J Pharmacol; 2011 Jan; 650(1):58-63. PubMed ID: 20950606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Milestones in understanding platelet production: a historical overview.
    Kuter DJ
    Br J Haematol; 2014 Apr; 165(2):248-58. PubMed ID: 24528208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?
    Sallmon H; Gutti RK; Ferrer-Marin F; Liu ZJ; Sola-Visner MC
    J Perinatol; 2010 Dec; 30(12):765-9. PubMed ID: 20410910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.
    Yang BB; Doshi S; Arkam K; Franklin J; Chow AT
    Clin Pharmacokinet; 2016 Sep; 55(9):1045-58. PubMed ID: 27056734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The new thrombopoietic agenda: impact on leukemias and MDS.
    Bussel JB
    Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
    Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
    Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
    Xie CY; Xu YP; Zhao HB; Lou LG
    Exp Hematol; 2012 May; 40(5):386-92. PubMed ID: 22269115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New thrombopoietin receptor agonists for platelet disorders.
    Homeida S; Ebdon C; Batty P; Jackson B; Kolade S; Bateman C; Peng YY; Stasi R
    Drugs Today (Barc); 2012 Apr; 48(4):293-301. PubMed ID: 22536571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular insights on Eltrombopag: potential mitogen stimulants, angiogenesis, and therapeutic radioprotectant through TPO-R activation.
    Subbarayan R; Srinivasan D; Shadula Osmania S; Murugan Girija D; Ikhlas S; Srivastav N; Balakrishnan R; Shrestha R; Chauhan A
    Platelets; 2024 Dec; 35(1):2359028. PubMed ID: 38832545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.
    Stasi R
    Expert Rev Hematol; 2008 Dec; 1(2):145-52. PubMed ID: 21082919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE; Rose MJ
    Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.